Adenomatous Polyps
Conditions
Keywords
Eicosapentaenoic acid, EPA, EPA 99%, Fatty acid, omega-3, apoptosis, cell proliferation, colonic mucosa, polyps, adenomatous polyps, endoscopy, PUFA
Brief summary
The purpose of this study is to determine the effect of two doses purified EPA (an omega-3 fatty acid), on apoptosis (natural cell death) and cell proliferation (formation of new cells) in the lining of the colon for patients with a history of colonic polyps.
Detailed description
Colorectal cancer is generally accepted to develop from changes within colonic adenomatous polyps. More than 90% of new large bowel cancers arise sporadically. The molecular events leading to the development of colorectal cancer from polyps are characterised by an imbalance in cell proliferation (formation of new cells) and apoptosis (natural cell death) from changes in the genes involved in normal colon cells. Recent work at St George's Hospital Medical School, London, has shown significant beneficial effects on cell proliferation and apoptosis rates in the lining of the colon in subjects with a history of colonic adenomas using a highly purified, free-fatty acid form of eicosapentaenoic acid (EPA). Comparator(s): 2g EPA per day for 6 months and 1g EPA per day for 6 months will be compared against placebo for 6 months.
Interventions
Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)
PROCEDUREEndoscopy
At baseline, month 3 and month 6.
PROCEDUREBiopsies taken
9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.
PROCEDUREClinical chemistry
Full blood count at baseline, month 3 and month 6.
PROCEDUREHaematology
Urea and electrolytes, liver function tests, clotting profile and CRP at baseline, month 3 and month 6.
PROCEDUREPhysical examination
Including cardio-respiratory and abdominal examination at baseline, month 3 and month 6.
PROCEDUREVital signs
Height, weight, heart rate, blood pressure and temperature at baseline, month 3 and month 6.
PROCEDUREUrine pregnancy test
For subjects of child-bearing potential, urine pregnancy test at baseline, month 3 and month 6.
PROCEDURECompletion of patient diary card
Subjects are requested to complete when study medication is taken and in any new or unusual symptoms are experienced on a daily basis for 6 months.
Sponsors
S.L.A. Pharma AG
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males or females aged over 18 * Patients of child-bearing potential must demonstrate a negative pregnancy test at screening, and should use a reliable form of contraception during the trial and for 1 month afterwards, e.g: * Oral contraceptive + condom * Intra-uterine device (IUD)+ condom * Diaphragm with spermicide + condom * Male partners of women of child bearing potential should use a reliable form of contraception during the trial and for 1 month afterwards, e.g: * Oral contraceptive + condom * Intra-uterine device (IUD)+ condom * Diaphragm with spermicide + condom * Patients must have a known history of colorectal adenomata and be under clinical follow-up for these, or be found to have one or more of these at the time of colonoscopy * Patients must have provided written informed consent to participate
Exclusion criteria
* Patients who are allergic to fish * Patients who have diabetes mellitus * Patients who are pregnant or breast-feeding * Patients taking aspirin or other non-steroidal anti-inflammatory drugs on a regular basis * Patients who have aspirin-sensitive asthma * Patients suffering from haemorrhagic disorders * Patients who are taking warfarin or other anticoagulants * Patients who have significant abnormalities on their screening blood tests * Patients taking lipid lowering medication * Patients with known inflammatory bowel disease (IBD), or previously unknown IBD until discovered at the time of their colonoscopy * Patients with gastrointestinal malabsorptive disease * Patients belonging to a known polyposis syndrome (e.g. FAP, HNPCC) * Patients with a previous colonic resection for colorectal cancer * Patients who are taking other fish-oil supplements (e.g. cod liver oil) who are unwilling to stop them for the duration of the study * Patients who are deemed mentally incompetent, or have a history of anorexia nervosa or bulimia * Patients with a history of alcohol or drug abuse, including laxative abuse * Patients considered by their physician unlikely to be able to comply with the protocol. * Patients who have taken part in an experimental drug study in the preceding 2 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To measure levels of apoptosis in the normal colonic mucosa in subjects with a history of colonic adenomas, before and after treatment with EPA 99%. | 3 months and 6 months |
| To measure levels of cell proliferation in the normal colonic mucosa in subjects with a history of colonic adenomas, before and after treatment with EPA 99%. | 3 months and 6 months |
Secondary
| Measure | Time frame |
|---|---|
| To measure the tissue content of EPA in the colonic mucosa before, during and after treatment with EPA. | 3 months and 6 months |
| To determine the safety and tolerability of EPA. | 3 months and 6 months |
Countries
Italy, United Kingdom
Outcome results
None listed